Abstract
Alzheimers disease is a progressive neurodegenerative disease characterized by gradual and increasing loss of cognitive function and behavioral abnormalities. The formation of β-amyloid plaques and neurofibrillary tangles are recognized as the key pathologies of the disease. Changes in the levels of various key neurotransmitters has been noted in patients with Alzheimers disease and may represent the earliest biochemical casualty, preceding or signifying the onset of the disease. Over the last 20 years a number of approaches to the palliative treatment of Alzheimers disease have been scrutinized. The majority of effort has been focused on cognitive dysfunction, as this is the initial and key debilitating symptom of the disease. The identification and commercial development of the acetylcholinesterase inhibitors has, until recently, virtually dominated the field, and although efficacy has been demonstrated, the clinical results suggest alternate approaches are warranted. This review will highlight those palliative approaches that have focused on the improvement of learning and memory and not on the disease-modifying strategies of the β-amyloid, tau phosphorylation or other neurodegenerative hypotheses.
Keywords: neurotransmission, neurodegeneration, cognitive dysfunction, cognition, Alzheimer's disease, Palliative
Current Topics in Medicinal Chemistry
Title: Approaches to Palliative Therapies for Alzheimers Disease
Volume: 6 Issue: 6
Author(s): Albert J. Robichaud
Affiliation:
Keywords: neurotransmission, neurodegeneration, cognitive dysfunction, cognition, Alzheimer's disease, Palliative
Abstract: Alzheimers disease is a progressive neurodegenerative disease characterized by gradual and increasing loss of cognitive function and behavioral abnormalities. The formation of β-amyloid plaques and neurofibrillary tangles are recognized as the key pathologies of the disease. Changes in the levels of various key neurotransmitters has been noted in patients with Alzheimers disease and may represent the earliest biochemical casualty, preceding or signifying the onset of the disease. Over the last 20 years a number of approaches to the palliative treatment of Alzheimers disease have been scrutinized. The majority of effort has been focused on cognitive dysfunction, as this is the initial and key debilitating symptom of the disease. The identification and commercial development of the acetylcholinesterase inhibitors has, until recently, virtually dominated the field, and although efficacy has been demonstrated, the clinical results suggest alternate approaches are warranted. This review will highlight those palliative approaches that have focused on the improvement of learning and memory and not on the disease-modifying strategies of the β-amyloid, tau phosphorylation or other neurodegenerative hypotheses.
Export Options
About this article
Cite this article as:
Robichaud J. Albert, Approaches to Palliative Therapies for Alzheimers Disease, Current Topics in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/156802606776743039
DOI https://dx.doi.org/10.2174/156802606776743039 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FDG PET/MR Imaging in Major Neurocognitive Disorders
Current Alzheimer Research Veno-Arterial Extracorporeal Membrane Oxygenation in the Adult: A Bridge to the State of the Art
Current Cardiology Reviews Alzheimer Disease and the Role of Free Radicals in the Pathogenesis of the Disease
CNS & Neurological Disorders - Drug Targets The Dualistic Nature of Immune Modulation In Alzheimers Disease: Lessons from the Transgenic Models
Current Pharmaceutical Design The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry An Overview of Recent Patents on Nanosuspension
Recent Patents on Drug Delivery & Formulation Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Editorial: Advances in Therapies of Cerebellar Disorders
CNS & Neurological Disorders - Drug Targets Malondialdehyde and Superoxide Dismutase in High-dose Calcium Supplemented Women in Relation to Iron and Calcium Panels
Current Nutrition & Food Science MicroRNA-451 Aggravates Kainic Acid-induced Seizure and Neuronal Apoptosis by Targeting GDNF
Current Neurovascular Research Functional Neuroproteomics: An Imperative Approach for Unravelling Protein Implicated Complexities of Brain
CNS & Neurological Disorders - Drug Targets Can Lipoprotein-associated Phospholipase A<sub>2</sub> be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?
Current Cardiology Reviews Meet Our Editorial Board Member
Current Neuropharmacology Management of Peyronie's Disease after Collagenase (Xiaflex:<sup>®</sup>)
Current Drug Targets The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor
Current Clinical Pharmacology Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Berberine in the Multi-Target Treatment of Senile Dementia
Current Topics in Medicinal Chemistry Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease
Current Alzheimer Research L-Acetylcarnitine: A Proposed Therapeutic Agent for Painful Peripheral Neuropathies
Current Neuropharmacology G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design